Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 23;10(6):1323. doi: 10.3390/jcm10061323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The tissue distribution of radiolabeled polatuzumab vedotin and unconjugated polatuzumab antibody after a single dose via IV administration in rats. (A) The tissue and blood radioactivity from intact (¹²⁵I radioactivity—solid bar) and catabolized (subtract ¹²⁵I radioactivity from ¹¹¹In radioactivity—open bar) polatuzumab vedotin dosed at the tracer (≈3 μg/kg) level up to 14 days post administration. (B) The tissues and blood radioactivity from intact (¹²⁵I radioactivity—solid bar) and catabolized (¹¹¹In subtracted with ¹²⁵I radioactivity—open bar) unconjugated polatuzumab antibody dosed at the tracer (≈3–4 μg/kg) level up to 14 days post administration. (C) The tissues and plasma radioactivity from conjugated (³H precipitated radioactivity—solid bar) and deconjugated (³H soluble radioactivity—open bar) [³H]-MMAE-polatuzumab vedotin dosed at 10 mg/kg up to 14 days post administration. A higher distribution of polatuzumab vedotin was observed in highly perfused tissues, such as the liver, spleen, and kidneys, and resulted in higher catabolism. The data are represented as the mean ± SD (except in (C) where only the mean is reported). n = 3 per time point. S. Intestine: small intestine; L. Intestine: large intestine; B. Marrows: bone marrows; A. gland: adrenal glands; DRG: dorsal root ganglions; Sc. Nerve: sciatic nerve.

The tissue distribution of radiolabeled polatuzumab vedotin and unconjugated polatuzumab antibody after a single dose via IV administration in rats. (A) The tissue and blood radioactivity from intact (¹²⁵I radioactivity—solid bar) and catabolized (subtract ¹²⁵I radioactivity from ¹¹¹In radioactivity—open bar) polatuzumab vedotin dosed at the tracer (≈3 μg/kg) level up to 14 days post administration. (B) The tissues and blood radioactivity from intact (¹²⁵I radioactivity—solid bar) and catabolized (¹¹¹In subtracted with ¹²⁵I radioactivity—open bar) unconjugated polatuzumab antibody dosed at the tracer (≈3–4 μg/kg) level up to 14 days post administration. (C) The tissues and plasma radioactivity from conjugated (³H precipitated radioactivity—solid bar) and deconjugated (³H soluble radioactivity—open bar) [³H]-MMAE-polatuzumab vedotin dosed at 10 mg/kg up to 14 days post administration. A higher distribution of polatuzumab vedotin was observed in highly perfused tissues, such as the liver, spleen, and kidneys, and resulted in higher catabolism. The data are represented as the mean ± SD (except in (C) where only the mean is reported). n = 3 per time point. S. Intestine: small intestine; L. Intestine: large intestine; B. Marrows: bone marrows; A. gland: adrenal glands; DRG: dorsal root ganglions; Sc. Nerve: sciatic nerve.